BCR-ABL tyrosine kinase inhibitors are recognized for their effectiveness in treating chronic myeloid leukemia (CML), acting through selective non-ATP competition to inhibit BCR-ABL tyrosine kinase activity. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.